On October 14, 2026 Affibody AB ("Affibody") reported a series of presentations at the 2026 Congress of the European Association of Nuclear Medicine (EANM), taking place October 17-21 in Vienna. The presentations span both clinical and preclinical research and include results from the ongoing Phase 1 study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer, clinical data with the HER2 PET imaging agent tezatabep matraxetan, and preclinical findings with Affibody molecules targeting B7-H3. Together, the presentations highlight the breadth of Affibody’s capabilities across targeted RLTs and precision imaging.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The wealth and diversity of results being presented at EANM, one of the world’s leading congresses in nuclear medicine and theranostics, reflects both the potential of our Affibody technology and the strength of our collaborations," said David Bejker, Chief Executive Officer of Affibody. "We are excited to see our science translate into meaningful advancements with the aim to address significant unmet needs in patients with hard-to-treat cancers."
Presentations
Title: A First-in-Human Phase 1 Trial Safety and Biodistribution of [¹⁷⁷Lu]Lu-ABY-271 in Subjects with HER2-Positive Metastatic Breast Cancer (NCT07081555)
Presenter: Joachim Feldwisch, Affibody
Session: C: Therapy Clinical Study – C1 Oncological Therapy Clinical Study – C16 Other Oncological Treatments
Format: e-Poster
Presentation ID: EP-0981
Title: Whole-body HER2 PET/CT reveals spatial heterogeneity of HER2 expression in advanced gastroesophageal adenocarcinoma.
Presenter: Antonios Tzortzakakis, Karolinska Institutet
Date and Time: October 18, 2026, 08:00 CEST
Session: Clinical Oncology Track: Gastro-Intestinal Malignancy
Format: Oral
Presentation ID: OP-035
Title: Standardization of image quality and activity quantification in a multi-centre PET imaging study (Ex-PET)
Presenter: Jakob Lagerstedt, Karolinska University Hospital
Date and Time: October 20, 2026, 16:45 CEST
Session: Cutting Edge Science Track: Physics Committee: Quantitative PET:
Harmonisation and Robustness
Format: Oral
Presentation ID: OP-734
Title: Preclinical Evaluation of PNABased Affibody-mediated Pretargeting for targeting HER2: A direct comparison between Tb-161 and Lu-177
Presenter: Maryam Oroujeni, Uppsala University
Date and Time: October 18, 2026, 09:45 CEST
Session: M2M Track: TROP Session – Radiopharmaceutical Sciences Committee: 161Tb vs 177Lu, and The Winner Is…
Format: Oral
Presentation ID: OP-084
Title: Modular Molecular Design of B7H3Targeting Affibody Molecules for Radionuclide Therapy: Biodistribution-Driven Selection and Therapy
Presenter: Maryam Oroujeni, Uppsala University
Date and Time: October 20, 2026, 16:45 CEST
Session: Radiopharmaceutical Sciences Committee: Modern Approaches to Drug Development in Nuclear Medicine
Format: Oral e-Poster
Presentation ID: EPS-223
Title: HER2-Ex PET trial: A multicentre, prospective, open-label study using [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2 antibody-drug conjugates in patients with metastatic breast cancer.
Presenter: Anna Kistner, Karolinska Institutet
Session: B: Imaging Clinical Studies – B1 Oncological Imaging Clinical Study – B13 Breast
Format: e-Poster
Presentation ID: EP-0261
Title: In vitro evaluation of Affibody molecules targeting B7-H3 for radionuclide therapy of neuroblastoma
Presenter: Maryam Oroujeni, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A11 In Vitro Studies
Format: e-Poster
Presentation ID: EP-0003
Title: Optimized Affibody Molecule targeting B7-H3 immune checkpoint: Improved Tumor Targeting Properties in a Syngeneic MC38 Model
Presenter: Enrique Recasens Pérez-Vera, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A18 New Radiopharmaceuticals – Therapy
Format: e-Poster
Presentation ID: EP-0171
Title: Feasibility of affibody-based pretargeted delivery of 225Ac
Presenter: Vladimir Tolmachev, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A18 New Radiopharmaceuticals – Therapy
Format: e-Poster
Presentation ID: EP-0161
Title: Biodistribution and dosimetry for PET imaging of HER2-receptor expression using [18F]-HER2 in metastatic breast cancer
Presenter: Ulrika Estenberg, Karolinska University Hospital
Session: B: Imaging Clinical Studies – B10 Dosimetry in Diagnostic Applications – B101 Dosimetry in Diagnostic Applications
Format: e-Poster
Presentation ID: EP-0617
View the EANM abstracts here: View Source
About ABY-271
ABY-271 is a Radioligand Therapy (RLT) candidate aimed at tumor cells that express HER2, regardless of their location in the body. The project builds on previous clinical research insights from the development of the PET imaging agent tezatabep matraxetan (ABY-025), showing that the candidate substance can bind to HER2 independently of the tumor origin. ABY-271 with the radioisotope lutetium-177 emits therapeutic beta radiation, exerting irreversible damage to the cancer cells.
About tezatabep matraxetan
Tezatabep matraxetan (ABY-025) is a Gallium-68-labeled PET tracer candidate that aims to enable non-invasive visualization of HER2 expression in cancer patients. The high affinity and rapid clearance of tezatabep matraxetan from blood and normal organs allows HER2 assessment within hours.
About HER2
HER2 is a protein that is involved in cell growth. HER2 is overexpressed by some types of cancer cells, including breast, stomach, esophageal, ovarian, bladder, and pancreatic cancers. HER2 may cause cancer cells to grow more quickly and spread to other parts of the body and HER2-positive cancers are therefore considered more aggressive than HER2-negative cancers. However, they are much more likely to respond to treatments that target the HER2 protein. HER2-targeted therapies can remain effective even after multiple lines of treatment.
About B7-H3
B7-H3 (also known as CD276) is a cell surface immunomodulatory glycoprotein overexpressed by many different types of cancers, whereas its expression is low in most normal organs and tissues. This makes it a promising target for cancer therapies. B7-H3 inhibits tumor specific immune responses and promotes tumor cell proliferation and invasion. High B7-H3 expression is generally associated with poor prognosis.
(Press release, Affibody, OCT 14, 2026, View Source [SID1234673454])